据创鉴汇不完全统计,6月23日至6月29日全球生物制药领域共披露27起交易事件,潜在交易总额近110亿美元。其中,交易类型以13起药物授权为主,所涉及的交易标的广泛覆盖蛋白质类药物、分子胶,抗体药物(单抗/双抗)、小分子抑制剂等。中国创新药对外授权合作持续活跃,11起超亿美元的大额交易中,涉及中国创新药公司作为转让方的交易达4起。荣昌生物与Vor Bio达成药物授权协议,以潜在总金额42.3亿美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.